** Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket
** AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments
** Symbravo is a combination of two medicines, meloxicam and rizatriptan
** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says
** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women
** AXSM gained 6.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。